ALT Quote, Financials, Valuation and Earnings

Pfizer Inc. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of 21.32%. Altimmune, Inc.'s return on equity of -56.24% beat Pfizer Inc.'s return on equity of 10.84%.

Altimmune, Inc. has a consensus price target of $17.88, signalling upside risk potential of 249.8%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Altimmune, Inc. has higher upside potential than Pfizer Inc., analysts believe Altimmune, Inc. is more attractive than Pfizer Inc..

Altimmune, Inc. has a beta of -0.029, which suggesting that the stock is 102.89% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $5K, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Altimmune, Inc.'s net income of -$19M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 21,107.47x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals, Inc. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of -103.13%. Altimmune, Inc.'s return on equity of -56.24% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34%.

Altimmune, Inc. has a consensus price target of $17.88, signalling upside risk potential of 249.8%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $127.00 which suggests that it could grow by 21.38%. Given that Altimmune, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..

Altimmune, Inc. has a beta of -0.029, which suggesting that the stock is 102.89% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 1.963, suggesting its more volatile than the S&P 500 by 96.257%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $5K, which are smaller than Rhythm Pharmaceuticals, Inc. quarterly revenues of $51.3M. Altimmune, Inc.'s net income of -$19M is higher than Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 21,107.47x versus 38.20x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals, Inc. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of --. Altimmune, Inc.'s return on equity of -56.24% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.

Altimmune, Inc. has a consensus price target of $17.88, signalling upside risk potential of 249.8%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $30.44 which suggests that it could grow by 10.75%. Given that Altimmune, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than Terns Pharmaceuticals, Inc..

Altimmune, Inc. has a beta of -0.029, which suggesting that the stock is 102.89% less volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $5K, which are larger than Terns Pharmaceuticals, Inc. quarterly revenues of --. Altimmune, Inc.'s net income of -$19M is higher than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 21,107.47x versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of --. Altimmune, Inc.'s return on equity of -56.24% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Altimmune, Inc. has a consensus price target of $17.88, signalling upside risk potential of 249.8%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 163.74%. Given that Altimmune, Inc. has higher upside potential than Viking Therapeutics, Inc., analysts believe Altimmune, Inc. is more attractive than Viking Therapeutics, Inc..

Altimmune, Inc. has a beta of -0.029, which suggesting that the stock is 102.89% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $5K, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Altimmune, Inc.'s net income of -$19M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 21,107.47x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.